| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BIOLOGICALS.2008.01.004 |
| P698 | PubMed publication ID | 18337119 |
| P50 | author | Fabian Käsermann | Q73233703 |
| P2093 | author name string | W Schäfer | |
| C Kempf | |||
| T Nowak | |||
| M Stucki | |||
| N Boschetti | |||
| A Gröner | |||
| T Hostettler | |||
| P433 | issue | 4 | |
| P921 | main subject | prion protein family | Q24724413 |
| P304 | page(s) | 239-247 | |
| P577 | publication date | 2008-03-12 | |
| P1433 | published in | Biologicals | Q4915041 |
| P1476 | title | Investigations of prion and virus safety of a new liquid IVIG product | |
| P478 | volume | 36 |
| Q50936515 | A Heparin Purification Process Removes Spiked Transmissible Spongiform Encephalopathy Agent. |
| Q46702304 | Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma |
| Q34261862 | Detection of prion protein particles in blood plasma of scrapie infected sheep |
| Q33385549 | Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura |
| Q34112793 | Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency |
| Q35566525 | Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency |
| Q48095460 | HPLC fingerprinting approach for raw material assessment and unit operation tracking for IVIG production from Cohn I+II+III fraction |
| Q38245612 | Hizentra for the treatment of primary immunodeficiency |
| Q38012531 | Immune globulin subcutaneous (human) 20%: in primary immunodeficiency disorders |
| Q39273058 | In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations |
| Q50954810 | Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products. |
| Q42254294 | Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate® P) in patients with haemophilia A. |
| Q40338659 | Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration |
| Q30582294 | Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies |
| Q37318222 | Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment |
| Q51763978 | Removal of prion infectivity by affinity ligand chromatography during OctaplasLG® manufacturing--results from animal bioassay studies. |
| Q46349815 | Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies |
| Q90590606 | Stress Factors in mAb Drug Substance Production Processes: Critical Assessment of Impact on Product Quality and Control Strategy |
| Q37890936 | Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach. |
| Q36196688 | Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases |
| Q37791323 | The New Generation of Liquid Intravenous Immunoglobulin Formulations in Patient Care: A Comparison of Intravenous Immunoglobulins |
| Q39015058 | Zika virus infection and biological treatment for reproductive medicine |
Search more.